503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25

📚 Book Relaunch: The book “Decoding GLP-1” is back on Amazon, now priced at $10, thanks to community advocacy. ⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25. 🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles. 💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access. 📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices. 🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies. 🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.